Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial
Abstract The aim was to assess the weight-reducing effects of various doses of a probiotic dietary supplement and evaluate the tolerance and safety of increased dosage. A 3-month double-blinded, randomized, placebo-controlled trial, followed by a 3-month open phase, was conducted at Karolinska Insti...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-45395-7 |
| _version_ | 1827711615438422016 |
|---|---|
| author | Pernilla Danielsson Resthie R. Putri Claude Marcus Emilia Hagman |
| author_facet | Pernilla Danielsson Resthie R. Putri Claude Marcus Emilia Hagman |
| author_sort | Pernilla Danielsson |
| collection | DOAJ |
| description | Abstract The aim was to assess the weight-reducing effects of various doses of a probiotic dietary supplement and evaluate the tolerance and safety of increased dosage. A 3-month double-blinded, randomized, placebo-controlled trial, followed by a 3-month open phase, was conducted at Karolinska Institutet, Sweden. The probiotic compound AB001 was tested at two doses (single and double) and compared with placebo during the blinded phase, and at triple dose during the open phase. Eighty-one volunteers, 18–45 years old, with overweight were included. The primary outcome was change in weight. Secondary outcomes were changes in; BMI, waist circumference, blood pressure, blood lipids, glucose metabolism, liver enzymes, vitamin levels, and bowel habits. After 3 months (n = 81), no difference in weight, BMI, waist circumference, blood pressure, or biomarkers were observed between the groups. Forty-five individuals continued with triple dose. The group with initial single dose decreased 0.93 ± 4.73 kg (p = 0.34), and the group with double dose initially decreased 1.93 ± 3.70 kg (p = 0.027). Reported changes in bowel habits and gastro-intestinal problems were similar for all doses. The results indicate that a long-term use of at least double dose AB001 may be more beneficial for weight loss than lower doses. However, in the double blinded phase, no differences between groups were found. The probiotic compound AB001 was well tolerated and can safely be used up to double dose for 90 days followed by triple dose for 90 days. Trial registration: Clinicaltrial.gov NCT04897698, registered on 21 May 2021. |
| first_indexed | 2024-03-10T17:57:06Z |
| format | Article |
| id | doaj.art-860b47648ebb410e90caf75f95645854 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-10T17:57:06Z |
| publishDate | 2023-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-860b47648ebb410e90caf75f956458542023-11-20T09:08:36ZengNature PortfolioScientific Reports2045-23222023-10-0113111110.1038/s41598-023-45395-7Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trialPernilla Danielsson0Resthie R. Putri1Claude Marcus2Emilia Hagman3Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska InstitutetDivision of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska InstitutetDivision of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska InstitutetDivision of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska InstitutetAbstract The aim was to assess the weight-reducing effects of various doses of a probiotic dietary supplement and evaluate the tolerance and safety of increased dosage. A 3-month double-blinded, randomized, placebo-controlled trial, followed by a 3-month open phase, was conducted at Karolinska Institutet, Sweden. The probiotic compound AB001 was tested at two doses (single and double) and compared with placebo during the blinded phase, and at triple dose during the open phase. Eighty-one volunteers, 18–45 years old, with overweight were included. The primary outcome was change in weight. Secondary outcomes were changes in; BMI, waist circumference, blood pressure, blood lipids, glucose metabolism, liver enzymes, vitamin levels, and bowel habits. After 3 months (n = 81), no difference in weight, BMI, waist circumference, blood pressure, or biomarkers were observed between the groups. Forty-five individuals continued with triple dose. The group with initial single dose decreased 0.93 ± 4.73 kg (p = 0.34), and the group with double dose initially decreased 1.93 ± 3.70 kg (p = 0.027). Reported changes in bowel habits and gastro-intestinal problems were similar for all doses. The results indicate that a long-term use of at least double dose AB001 may be more beneficial for weight loss than lower doses. However, in the double blinded phase, no differences between groups were found. The probiotic compound AB001 was well tolerated and can safely be used up to double dose for 90 days followed by triple dose for 90 days. Trial registration: Clinicaltrial.gov NCT04897698, registered on 21 May 2021.https://doi.org/10.1038/s41598-023-45395-7 |
| spellingShingle | Pernilla Danielsson Resthie R. Putri Claude Marcus Emilia Hagman Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial Scientific Reports |
| title | Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial |
| title_full | Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial |
| title_fullStr | Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial |
| title_full_unstemmed | Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial |
| title_short | Evaluating probiotic efficacy on weight loss in adults with overweight through a double-blind, placebo-controlled randomized trial |
| title_sort | evaluating probiotic efficacy on weight loss in adults with overweight through a double blind placebo controlled randomized trial |
| url | https://doi.org/10.1038/s41598-023-45395-7 |
| work_keys_str_mv | AT pernilladanielsson evaluatingprobioticefficacyonweightlossinadultswithoverweightthroughadoubleblindplacebocontrolledrandomizedtrial AT resthierputri evaluatingprobioticefficacyonweightlossinadultswithoverweightthroughadoubleblindplacebocontrolledrandomizedtrial AT claudemarcus evaluatingprobioticefficacyonweightlossinadultswithoverweightthroughadoubleblindplacebocontrolledrandomizedtrial AT emiliahagman evaluatingprobioticefficacyonweightlossinadultswithoverweightthroughadoubleblindplacebocontrolledrandomizedtrial |